Evaluation of survival rate using liposome containing soluble antigens (SA) against Toxoplasma gondii infection in BALB/c mice

Document Type : Research Paper

Authors

1 Infectious Diseases and Tropical Medicine Research Center, Resistant Tuberculosis Institute, Zahedan University of Medical Sciences, Zahedan, Iran

2 Department of Parasitology and Mycology, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

3 Toxoplasmosis Research Center, Department of Medical Nanotechnology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

Objective(s): Toxoplasma gondii, an obligate intracellular protozoan parasite, is widespread across the world. It causes congenital disease and abortion in humans and domestic animals. One of the major concerns in parasitology, thus, is an effective vaccine development to control Toxoplasmosis.
Materials and Methods: In the present research, a nano-liposomal vaccine containing soluble antigens (SA) was designed to evaluate the immunity and protective efficacy against T. gondii infection in BALB/c mice. Soluble antigens (SA) were achieved from tachyzoites, encapsulated in the liposome, and investigated via scanning electron microscope. Three times with 2-week intervals, BALB/c mice were immunized subcutaneously with different formulations. The level of protection against infection was assessed through the percent survival survey of BALB/c mice after challenge with tachyzoites of T. gondii RH strain; also, the type of generated immune response was determined by evaluating the generation of cytokine (IFN-γ, IL-4) and titration of IgG isotypes.
Results: The immunization with liposome DSPC+ SA and liposome DSPC+ Imiquimod + SA induced a substantial increase in anti-Toxoplasma IgG antibody as compared to the PBS group (p <0.05). The IgG2a and IFN-γ secretion highest levels were seen with liposome DSPC+ Imiquimod + SA more than the control group (p <0.01) and (p <0.0001), respectively. After challenge with tachyzoites, less mortality was detected in the immunized mice by liposome DSPC + Imiquimod + SA that was meaningfully different (p <0.01) in comparison to other groups.
Conclusion: Vaccination with liposome DSPC + Imiquimod + SA showed more survival rate and cellular immune reaction against T. gondii.

Keywords

References

1.Jafari Modrek M, Hasanzadeh R, Foroutan M, Mirahmadi H, Rahmati-Balaghaleh M, Zarean M. Seroprevalence and molecular evaluation of Toxoplasma gondii in Schizophrenic patients hospitalized in Sistan and Baluchestan province, Southeast of Iran. Trop Biomed. 2018; 36: 422-429.
2.Meroni V, Genco F. Toxoplasmosis in pregnancy: evaluation of diagnostic methods. Parassitologia. 2008; 50: 51.
3.Rahmati-Balaghaleh M, Farash BRH, Zarean M, Hatami-Pourdehno S, Mirahmadi H, Jarahi L, et al. Diagnosis of acute toxoplasmosis by IgG avidity method in pregnant women referred to health centers in south-eastern Iran. J Parasit Dis. 2019; 43: 517-521.
4.Ahmadpour E, Daryani A, Sharif M, Sarvi S, Aarabi M, Mizani A, et al. Toxoplasmosis in immunocompromised patients in Iran: a systematic review and meta-analysis. J Infec  Dev Ctries. 2014; 8: 1503-1510.
5.Zhang N-Z, Chen J, Wang M, Petersen E, Zhu X-Q. Vaccines against Toxoplasma gondii: new developments and perspectives. Expert Rev Vaccines. 2013; 12: 1287-1299.
6. Hiszczyńska-Sawicka E, Gatkowska JM, Grzybowski MM, Długońska H. Veterinary vaccines against toxoplasmosis. Parasitology. 2014; 141: 1365-1378.
7.Daryani A, Hosseini AZ, Dalimi A. Immune responses against excreted/secreted antigens of Toxoplasma gondii tachyzoites in the murine model. Vet Parasitol. 2003; 113: 123-134.
8.Daryani A, Kalani H, Sharif M, Ziaei H, Sarvi S, Ahmadpour E. Toxoplasma gondii: a review of excretory secretory antigens. J Mazandaran Univ Med Sci. 2013; 22: 220-232.
9.Sun B, Xia T. Nanomaterial-based vaccine adjuvants. J Mater Chem B. 2016; 4: 5496-5509.
10.Mehravaran A, Nasab MR, Mirahmadi H, Sharifi I, Alijani E, Nikpoor AR, et al. Protection induced by Leishmania Major antigens and the imiquimod adjuvant encapsulated on liposomes in experimental cutaneous leishmaniasis. Infec Genet Evol. 2019; 70: 27-35.
11.Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014; 2: 159-182.
12.Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4: 145.
13.Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother. 2014; 10: 2761-2774.
14.Kalani H, Daryani A, Sharif M, Ahmadpour E, Alizadeh A, Nasrolahei M, et al. Comparison of eight cell-free media for maintenance of Toxoplasma gondii tachyzoites. Iran J Parasitol. 2016; 11: 104.
15.Bainor A, Chang L, McQuade TJ, Webb B, Gestwicki JE. Bicinchoninic acid (BCA) assay in low volume. Anal Biochem. 2011; 410: 310-312.
16.Daryani A, Sharif M, Kalani H, Rafiei A, Kalani F, Ahmadpour E. Electrophoretic patterns of Toxoplasma gondii excreted/secreted antigens and their role in induction of the humoral immune response. Jundishapur J Microbiol. 2014; 7(4):e9525
17.Dadimoghaddam Y, Daryani A, Sharif M, Ahmadpour E, Hossienikhah Z. Tissue tropism and parasite burden of Toxoplasma gondii RH strain in experimentally infected mice. Asian Pac J Trop Med. 2014; 7: 521-524.
18.Rahimi MT, Sarvi S, Sharif M, Abediankenari S, Ahmadpour E, Valadan R, et al. Immunological evaluation of a DNA cocktail vaccine with co-delivery of calcium phosphate nanoparticles (CaPNs) against the Toxoplasma gondii RH strain in BALB/c mice. Parasitol Res. 2017; 116: 609-616.
19.Azadi Y, Ahmadpour E, Hamishehkar H, Daryani A, Spotin A, Mahami-Oskouei M, et al. Quantification of Toxoplasma gondii in the tissues of BALB/c mice after immunization with nanoliposomal excretory-secretory antigens using Real-Time PCR. Comp Immunol Microbiol Infec Dis. 2018; 59: 52-56.
20.Foroutan M, Zaki L, Ghaffarifar F. Recent progress in microneme-based vaccines development against Toxoplasma gondii. Clin Exp Vaccine Res. 2018; 7: 93-103.
21.Foroutan M, Ghaffarifar F, Sharifi Z, Dalimi A. Vaccination with a novel multi-epitope ROP8 DNA vaccine against acute Toxoplasma gondii infection induces strong B and T cell responses in mice. Comp Immunol Microbiol Infect Dis. 2020; 69:101413.
22.Azadi Y, Ahmadpour E, Ahmadi A. Targeting strategies in therapeutic applications of Toxoplasmosis; Recent advances in liposomal vaccine delivery systems. Curr Drug Targets. 2020; 21(6):541-558.
23.Daryani A, Sharif M, Dadimoghaddam Y, Souteh MBH, Ahmadpour E, Khalilian A, et al. Determination of parasitic load in different tissues of murine toxoplasmosis after immunization by excretory–secretory antigens using Real time QPCR. Exp Parasitol. 2014; 143: 55-59.
24.Maji M, Mazumder S, Bhattacharya S, Choudhury ST, Sabur A, Shadab M, et al. A lipid based antigen delivery system efficiently facilitates MHC class-I antigen presentation in dendritic cells to stimulate CD8+ T cells. Sci Rep. 2016; 6: 1-12.
25.Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016; 44: 381-391.
26.Gunti S, Messer RJ, Xu C, Yan M, Coleman WG, Peterson KE, et al. Stimulation of toll-like receptors profoundly influences the titer of polyreactive antibodies in the circulation. Sci Rep. 2015; 5: 15066.
27.Perrie Y, Crofts F, Devitt A, Griffiths HR, Kastner E, Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv Rev. 2016; 99: 85-96.
28.Khamesipour A. Therapeutic vaccines for leishmaniasis. Expert Opin Biol Ther. 2014; 14: 1641-1649.
29.El-Zawawy LA, El-Said D, Mossallam SF, Ramadan HS, Younis SS. Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii. Acta Trop. 2015; 141: 103-111.
30.Tanaka S, Kuroda Y, Ihara F, Nishimura M, Hiasa J, Kojima N, et al. Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii. Vaccine. 2014; 32: 1781-1785.
31.Fatoohi A, Cozon G, Gonzalo P, Mayencon M, Greenland T, Picot S, et al. Heterogeneity in cellular and humoral immune responses against Toxoplasma gondii antigen in humans. Clin Exp Immunol. 2004; 136: 535-541.
32.Chen R, Lu S-h, Tong Q-b, Lou D, Shi D-y, Jia B-b, et al. Protective effect of DNA-mediated immunization with liposome-encapsulated GRA4 against infection of Toxoplasma gondii. J Zhejiang Univ Sci B. 2009; 10: 512-521.
33.Buates S, Matlashewski G. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother. 2001; 45: 1137-1142.
34.Raman VS, Reed SG, Duthie MS, Fox CB, Matlashewski G. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol. 2012; 3: 144.
35.Gupta N, Hartmann A, Lucius R, Voelker DR. The obligate intracellular parasite Toxoplasma gondii secretes a soluble phosphatidylserine decarboxylase. J Biol Chem. 2012; 287: 22938-22947.
36.Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015; 10: 81-98.
37.Badiee A, Jaafari MR, Khamesipour A, Samiei A, Soroush D, Kheiri MT, et al. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf B Biointerfaces. 2009; 74: 37-44.
38.Askarizadeh A, Jaafari MR, Khamesipour A, Badiee A. Liposomal adjuvant development for leishmaniasis vaccines. Ther Adv Vaccines. 2017; 5: 85-101.
39.Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release. 2010; 145: 102-108.
40.Christensen D, Korsholm K, Andersen P, Agger E. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines. 2011; 10: 513–521.
41.Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′, N′-dimethylaminoethane) carbomyl] cholesterol (DC-Chol), and 1, 2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharm. 2011; 8: 153-161.
Nanomedicine Journal
Volume 8, Issue 3
July 2021
Pages 179-186

Files

Share

How to cite

Statistics